Funding for this research was provided by:
Genome Canada
Article History
Received: 3 April 2020
Accepted: 1 September 2020
First Online: 13 October 2020
Ethics approval and consent to participate
: Ethics approval for this study was obtained by the University of British Columbia – BC Cancer Research Ethics Board (H18–00490).
: Not applicable.
: Adam Raymakers reports having received compensation from the Canadian Agency for Drugs and Technologies in Health (specifically from the pan-Canadian Oncology Drug Review for providing economic guidance about oncology drug submissions). Dean Regier has received funding unrelated to this work for conference travel from Illumina and honoraria from Roche.